UK Government Plays Matchmaker In GSK/Novavax Deal To ‘Onshore’ COVID-19 Vaccine Production
Comes Amid Tensions With EU
The UK wants to consolidate its rapid vaccine roll-out and its domestic supply chain via the alliance
You may also be interested in...
After setting up a sales base in the UK, Serum Institute could consider an acquisition in Europe or investment in an Oxford facility as it ties up production for its multiple COVID-19 vaccines. Is Wockhardt’s Wrexham facility an option?
Top-line Phase II data show that a combo of bamlanivimab and VIR-7831, neutralizing antibodies to the SARS-CoV-2 spike protein, yielded a relative 70% reduction in viral load.
Investors are anxious about the delay to Novavax’s deal with the EU, and want to know how and when it might file the vaccine with regulators.